Andrii Yalanskyi/iStock via Getty Images
I started following Halozyme Therapeutics, Inc. (HALO) in August 2024, and the company continues to deliver value to shareholders while growing a stream of royalty payments at a significant pace. They recently released
296 Followers
Analyst’s Disclosure: I/we have a beneficial long position in the shares of HALO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
I'm not an investment professional or investment advisor. This article is solely based on my own opinions and research. This is not meant to be a recommendation of the sale or the purchase of any securities. Investors should conduct their own research and perform their own due diligence before making any investment decisions.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。